Resumen
This article investigates the cutaneous adverse immune effects induced by immune checkpoint inhibitors. These drugs target proteins expressed on cancer cells that aid in the avoidance of immune system detection and destruction. Immune checkpoint inhibitors inadvertently cause other immune-mediated adverse effects. Cutaneous toxicities are the commonest adverse effect from immunotherapy; furthermore, they are usually developed early in the course of treatment. A rare and severe cutaneous adverse event is Bullous Pemphigoid. This article investigates the average and median onset of these drug toxicities, as well as treatments. We found these side effects to be negatively skewed, indicating most cases occur several months into treatment.